NCT00727727已完成不适用
Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 750
- 试验地点
- 1
- 主要终点
- to monitor use in daily routine practice including adverse events
研究概览
简要总结
The objective of the Post Marketing Surveillance Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Neurologists in private practices in Germany should document the safety and course of the disease/change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonist treatment under routine conditions. Piribedil should be prescribed according to its marketing authorisation.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients 18 years and older.
- •Indication: Morbus Parkinson.
- •Treatment with piribedil for the first time.
- •Monotherapy with piribedil.
- •Combination therapy with L-Dopa (from the beginning or secondary in combination with other antiparkinsonian drugs).
排除标准
- 未提供
研究组 & 干预措施
Parkinsonian patients
干预措施: Piribedil (Drug)
结局指标
主要结局
to monitor use in daily routine practice including adverse events
时间窗: 3 months
次要结局
- to monitor use in daily routine practice including efficacy aspects(3 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's DiseaseParkinson's DiseaseNCT00725478Desitin Arzneimittel GmbH250
已完成
不适用
Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®Breast NeoplasmNCT03445637Pfizer552
已完成
不适用
Vardenafil Treatment Of Erectile Dysfunction In Depressive And Non-Depressive MenErectile DysfunctionNCT00470873Bayer2,471
已完成
不适用
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in ChinaPsoriasisNCT03236870AbbVie181
终止
不适用
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)Multiple MyelomaNCT01947309Celgene176